Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.82%
#4 aPriori aPriori +148.53%
#5 Bedrock Bedrock +75.14%
#6 Cysic Cysic +50.00%
#7 Prom Prom +47.31%
#8 Playnance Playnance +34.96%
#9 Bitway Bitway +29.10%
#10 COTI COTI +25.76%
Coin of the day
Wrapped One Wrapped One
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOBI
Rang în acțiuni #1377
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Preț acțiune
$49.68
Capitalizare de piață
$17.25B
Schimbare (1 zi)
0.77%
Schimbare (1 an)
72.50%
Țară
SE
Tranzacționează Swedish Orphan Biovitrum AB (SOBI)

Categorie

Healthcare
Istoricul spliturilor pentru Swedish Orphan Biovitrum AB (SOBI)
Acțiunea Swedish Orphan Biovitrum AB (simbol: SOBI) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Aug 12, 2026.
O acțiune SOBI cumpărată înainte de Aug 12, 2026 este echivalentă astăzi cu 0 acțiuni SOBI.
Listă splituri acțiuni
An Split Multiplu Multiplu cumulativ
Nu sunt suficiente date pentru perioada selectată.
Splituri pentru companii similare sau competitori
Companie Număr total de splituri Multiplu cumulativ Țara
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 0 -
US
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 0 -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 0 -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 0 -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 7 x40
HK